This underscores why simply not eating, which is effectively what some people do when they first start retatrutide and let side effects dictate their nutrition, is the worst possible approach
(Triumph Pan European Expert Panel) (October 2002)
Learn more in our fact sheet
Recent phase 3 TRIUMPH4 data (Dec 2025) showed 28.7% loss over 68 weeks, exceeding semaglutide (1517.5%) and tirzepatide (22.5%)
Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives
doi: 10.3389/fpsyt.2019.00097 Received 27 November 2018 Accepted 11 February 2019 Published 01 March 2019 Volume 10 - 2019 Edited by Fernando Rodriguez de Fonseca, University of Mlaga, Spain Reviewed by Gregg Stanwood, Florida State University, United States